ePatient / Health 2.0 - A Key Factor for New and Innovative Business Models for the Life Sciences Industry

17 November 2011, Düsseldorf, Germany.
InterComponentWare AG (ICW), an internationally focused company specializing in technology solutions for the healthcare market, invites to a podium discussion during the Medica Media Forums. Follow the newest discussions at Medica 2011 in Düsseldorf and take advantage of the opportunity to discuss with subject matter experts. ICW representatives are looking forward to meeting you at 3:00 pm on Thursday, 17th November 2011 at the MEDICA Media Forum in Hall 15 (Stand A11).

Today's patients are well informed and capable of making their own decisions when it comes to healthcare. When making their decisions about health products and services they utilize both real-world channels and electronic channels of the internet. Increasingly, the "ePatient" is becoming a factor in the "Health 2.0 ecosystem".

ICW develops innovative solutions for the healthcare system under the slogan "connect. manage. personalize." Get a new perspective and discover how solutions from ICW can help you to network disparate actors, support care-critical processes, and create options for modern interaction to engage the patient in the treatment process.

Take time to visit ICW at MEDICA in Hall 15, Stand F35 to get an interesting look at modern eHealth solutions.

Arrange a personal appointment here: http://www.icw-global.com/en/press-events/medica-appointment.html, or send an email to Mr. Silvio Frey This email address is being protected from spambots. You need JavaScript enabled to view it.
Upon request ICW representatives will also gladly send complementary admission tickets or informational material.

About ICW
ICW is an international healthcare technology provider. Our robust software and techniologies help to network the various actors, optimize care and engage patients in the treatment process. Our products are based on the ICW eHealth Platform, a suite of powerful technology components that support the quick assembly of eHealth solutions and the flexible implementation of integration scenarios. Together with our partners, our goal is to enable interoperability among healthcare stakeholders to harvest potentials and realize innovative forms of cooperation and collaboration. For more information go to www.icw-global.com.

Most Popular Now

Study finds lack of racial diversity in cancer dru…

New research published in JAMA Oncology has found a lack of racial and ethnic diversity in clinical trials for cancer drugs. The study - conducted by researchers from UBC...

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Roche's first FDA-approved tumour-agnostic medicin…

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved Rozlytrek™ (entrectinib) for the treatment of adults with R...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

Amgen and Allergan announce positive top-line resu…

Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a comparative clinical study evaluating the efficacy and safety of ABP 798...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...